Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs semaglutide vs placebo in overweight and obesity (China, Phase 3)
CTR20232030Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of CagriSema in Overweight, obesity, type 2 diabetes mellitus (T2DM), hypertension (HTN), dyslipidemia, sponsored by Novo Nordisk. Started Jul 2023; status: completed.
02
Drugs
CagriSema
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on CTR20232030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232030.